Post‐treatment urinary sarcosine as a predictor of recurrent relapses in patients with prostate cancer
Abstract To date, there has been no evidence regarding the association between urinary sarcosine content and prostate cancer survival. Our main objective was to investigate whether levels of post‐treatment urinary sarcosine are associated with relapse. The inclusion criteria were (in accordance with...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-11-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.1767 |
| _version_ | 1797681429272854528 |
|---|---|
| author | Jaromir Gumulec Martina Raudenska Dalibor Pacik Mariana Plevova Alena Sorokac‐Kubolkova Zuzana Lackova Natalia Cernei Vladislav Strmiska Ondrej Zitka Zbynek Heger Vojtech Adam |
| author_facet | Jaromir Gumulec Martina Raudenska Dalibor Pacik Mariana Plevova Alena Sorokac‐Kubolkova Zuzana Lackova Natalia Cernei Vladislav Strmiska Ondrej Zitka Zbynek Heger Vojtech Adam |
| author_sort | Jaromir Gumulec |
| collection | DOAJ |
| description | Abstract To date, there has been no evidence regarding the association between urinary sarcosine content and prostate cancer survival. Our main objective was to investigate whether levels of post‐treatment urinary sarcosine are associated with relapse. The inclusion criteria were (in accordance with EAU 2017) as follows: histopathologically verified adenocarcinoma in prostate biopsy cores or specimens from transurethral resection of the prostate (TURP) or prostatectomy for benign prostatic enlargement (BPE) with retained ability to urinate. The median follow‐up was 53 months. In the study, we retrospectively evaluated a cohort of 511 patients with prostate cancer with various risk factors and treatment strategies. Post‐treatment sarcosine levels were elevated in 266 (52%) patients and highly elevated (≥200 nmol/L) in 71 (13%) patients. Urinary sarcosine content was significantly associated with number of relapses that patients experienced, P = 0.002 for sarcosine ≥200 vs ≤30 nmol/L. Multivariate analysis revealed that sarcosine was an independent predictor of recurrent relapses (≥2 relapses with an intermediate period of remission), HR = 3.89 (95% CI 1.29‐11.7) for sarcosine >200 vs <30 nmol/L. This trend was even more pronounced in a subgroup of patients who underwent radical prostatectomy, HR = 3.29 (95% CI 1.06‐10.18), where (single) relapse‐free survival could also be predicted by sarcosine levels, HR = 1.96 (1.05‐3.66). Urinary sarcosine may become a possible predictor for patients’ outcomes, because patients with elevated post‐treatment sarcosine could be predicted to have recurrent relapses of the disease. |
| first_indexed | 2024-03-11T23:44:42Z |
| format | Article |
| id | doaj.art-23ba84d7c5024a24bea68eaadc3f180f |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-03-11T23:44:42Z |
| publishDate | 2018-11-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-23ba84d7c5024a24bea68eaadc3f180f2023-09-19T11:30:57ZengWileyCancer Medicine2045-76342018-11-017115411541910.1002/cam4.1767Post‐treatment urinary sarcosine as a predictor of recurrent relapses in patients with prostate cancerJaromir Gumulec0Martina Raudenska1Dalibor Pacik2Mariana Plevova3Alena Sorokac‐Kubolkova4Zuzana Lackova5Natalia Cernei6Vladislav Strmiska7Ondrej Zitka8Zbynek Heger9Vojtech Adam10Department of Pathological Physiology Faculty of Medicine Masaryk University Brno Czech RepublicDepartment of Pathological Physiology Faculty of Medicine Masaryk University Brno Czech RepublicDepartment of Urology University Hospital Brno Faculty of Medicine Masaryk University Brno Czech RepublicDepartment of Urology University Hospital Brno Faculty of Medicine Masaryk University Brno Czech RepublicDepartment of Urology University Hospital Brno Faculty of Medicine Masaryk University Brno Czech RepublicDepartment of Chemistry and Biochemistry Mendel University in Brno Brno Czech RepublicCentral European Institute of Technology Brno University of Technology Brno Czech RepublicDepartment of Chemistry and Biochemistry Mendel University in Brno Brno Czech RepublicDepartment of Chemistry and Biochemistry Mendel University in Brno Brno Czech RepublicDepartment of Chemistry and Biochemistry Mendel University in Brno Brno Czech RepublicDepartment of Chemistry and Biochemistry Mendel University in Brno Brno Czech RepublicAbstract To date, there has been no evidence regarding the association between urinary sarcosine content and prostate cancer survival. Our main objective was to investigate whether levels of post‐treatment urinary sarcosine are associated with relapse. The inclusion criteria were (in accordance with EAU 2017) as follows: histopathologically verified adenocarcinoma in prostate biopsy cores or specimens from transurethral resection of the prostate (TURP) or prostatectomy for benign prostatic enlargement (BPE) with retained ability to urinate. The median follow‐up was 53 months. In the study, we retrospectively evaluated a cohort of 511 patients with prostate cancer with various risk factors and treatment strategies. Post‐treatment sarcosine levels were elevated in 266 (52%) patients and highly elevated (≥200 nmol/L) in 71 (13%) patients. Urinary sarcosine content was significantly associated with number of relapses that patients experienced, P = 0.002 for sarcosine ≥200 vs ≤30 nmol/L. Multivariate analysis revealed that sarcosine was an independent predictor of recurrent relapses (≥2 relapses with an intermediate period of remission), HR = 3.89 (95% CI 1.29‐11.7) for sarcosine >200 vs <30 nmol/L. This trend was even more pronounced in a subgroup of patients who underwent radical prostatectomy, HR = 3.29 (95% CI 1.06‐10.18), where (single) relapse‐free survival could also be predicted by sarcosine levels, HR = 1.96 (1.05‐3.66). Urinary sarcosine may become a possible predictor for patients’ outcomes, because patients with elevated post‐treatment sarcosine could be predicted to have recurrent relapses of the disease.https://doi.org/10.1002/cam4.1767outcomeprostate cancerrelapsesarcosinesurvival |
| spellingShingle | Jaromir Gumulec Martina Raudenska Dalibor Pacik Mariana Plevova Alena Sorokac‐Kubolkova Zuzana Lackova Natalia Cernei Vladislav Strmiska Ondrej Zitka Zbynek Heger Vojtech Adam Post‐treatment urinary sarcosine as a predictor of recurrent relapses in patients with prostate cancer Cancer Medicine outcome prostate cancer relapse sarcosine survival |
| title | Post‐treatment urinary sarcosine as a predictor of recurrent relapses in patients with prostate cancer |
| title_full | Post‐treatment urinary sarcosine as a predictor of recurrent relapses in patients with prostate cancer |
| title_fullStr | Post‐treatment urinary sarcosine as a predictor of recurrent relapses in patients with prostate cancer |
| title_full_unstemmed | Post‐treatment urinary sarcosine as a predictor of recurrent relapses in patients with prostate cancer |
| title_short | Post‐treatment urinary sarcosine as a predictor of recurrent relapses in patients with prostate cancer |
| title_sort | post treatment urinary sarcosine as a predictor of recurrent relapses in patients with prostate cancer |
| topic | outcome prostate cancer relapse sarcosine survival |
| url | https://doi.org/10.1002/cam4.1767 |
| work_keys_str_mv | AT jaromirgumulec posttreatmenturinarysarcosineasapredictorofrecurrentrelapsesinpatientswithprostatecancer AT martinaraudenska posttreatmenturinarysarcosineasapredictorofrecurrentrelapsesinpatientswithprostatecancer AT daliborpacik posttreatmenturinarysarcosineasapredictorofrecurrentrelapsesinpatientswithprostatecancer AT marianaplevova posttreatmenturinarysarcosineasapredictorofrecurrentrelapsesinpatientswithprostatecancer AT alenasorokackubolkova posttreatmenturinarysarcosineasapredictorofrecurrentrelapsesinpatientswithprostatecancer AT zuzanalackova posttreatmenturinarysarcosineasapredictorofrecurrentrelapsesinpatientswithprostatecancer AT nataliacernei posttreatmenturinarysarcosineasapredictorofrecurrentrelapsesinpatientswithprostatecancer AT vladislavstrmiska posttreatmenturinarysarcosineasapredictorofrecurrentrelapsesinpatientswithprostatecancer AT ondrejzitka posttreatmenturinarysarcosineasapredictorofrecurrentrelapsesinpatientswithprostatecancer AT zbynekheger posttreatmenturinarysarcosineasapredictorofrecurrentrelapsesinpatientswithprostatecancer AT vojtechadam posttreatmenturinarysarcosineasapredictorofrecurrentrelapsesinpatientswithprostatecancer |